India's Venus Remedies jumps on market authorisation for cancer drug in UK

Venus Remedies

26/10/2023 06:23

** Shares of Venus Remedies  VENR.NS  surge as much as 9.29%
to 258.15 rupees per share, before erasing gains amid selling
pressure in markets
    ** Pharmaceutical company's unit receives market
authorisation in the United Kingdom for Bleomycin, a drug used
in chemotherapy to treat cancer
    ** VENR now has a total of 15 market authorisations globally
for the chemotherapy drug
    ** Trading volume is 103,645 shares as of 10:46 a.m. IST,
twice the 30-day avg - LSEG data
    ** Including day's gains, VENR shares up 31.3% in 2023 so
far

 (Reporting by Bharath Rajeswaran in Bengaluru)
 ((bharath.rajeswaran@thomsonreuters.com; +91 9769003463))